These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26381215)

  • 1. Depression Worsening Associated With Lorcaserin: A Case Report.
    Rakofsky JJ; Tang Y; Dunlop BW
    J Clin Psychopharmacol; 2015 Dec; 35(6):747-8. PubMed ID: 26381215
    [No Abstract]   [Full Text] [Related]  

  • 2. Lorcaserin for weight loss: insights into US Food and Drug Administration approval.
    Miller LE
    J Acad Nutr Diet; 2013 Jan; 113(1):25-30. PubMed ID: 23260720
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and tolerability review of lorcaserin in clinical trials.
    Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
    Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of lorcaserin in the management of obesity.
    Hess R; Cross LB
    Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2 new drugs for weight loss.
    Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
    [No Abstract]   [Full Text] [Related]  

  • 7. Multicenter, placebo-controlled trial of lorcaserin for weight management.
    Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
    N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555
    [No Abstract]   [Full Text] [Related]  

  • 9. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
    Nguyen CT; Zhou S; Shanahan W; Fain R
    Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC; Luon D; Baker WL
    Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
    Higgins GA; Fletcher PJ; Shanahan WR
    Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
    Hurren KM; Berlie HD
    Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug management of obesity--efficacy versus safety.
    Astrup A
    N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205
    [No Abstract]   [Full Text] [Related]  

  • 14. "Selectivity": an attractive but often misleading notion.
    Prescrire Int; 2014 May; 23(149):120. PubMed ID: 24926509
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemistry, Analysis, Pharmacokinetics and Pharmacodynamics Aspects of Lorcaserin, a Selective Serotonin 5-HT2C Receptor Agonist: An Update.
    Sharma S; Aware KS; Hatware K; Patil K
    Mini Rev Med Chem; 2020; 20(9):768-778. PubMed ID: 30961494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oral anti-obesity agents: new perspectives with lorcaserin?
    Gallwitz B
    Drugs; 2013 Apr; 73(5):393-5. PubMed ID: 23532530
    [No Abstract]   [Full Text] [Related]  

  • 17. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.
    Bays HE
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1429-45. PubMed ID: 19900026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Has the bloom gone out of lorcaserin following the CAMELLIA-TIMI61 trial?
    Mathai ML
    Expert Opin Pharmacother; 2021 Feb; 22(3):261-264. PubMed ID: 33382010
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial.
    Sharretts J; Galescu O; Gomatam S; Andraca-Carrera E; Hampp C; Yanoff L
    N Engl J Med; 2020 Sep; 383(11):1000-1002. PubMed ID: 32905671
    [No Abstract]   [Full Text] [Related]  

  • 20. Lorcaserin. In obesity: unacceptable risks.
    Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.